clinical trial · NCT06544798
Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
MeiraGTx, LLC·phase2·enrolling by invitation·n = 276
Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid GlandsAAV2-hAQP1
brief summary
This study will assess the long-term safety and efficacy of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
started
Aug 2, 2024
primary completion
Feb 1, 2032
completion
Feb 1, 2032
last updated
Oct 16, 2025
detailed description
Individual participation in this study will last approximately 48 months for participants who received AAV2-hAQP1 in Study MGT-AQP1-201 and at least 60 months for participants who receive AAV2-hAQP1 in Study MGT-AQP1-202.
official title
Long-term Follow-up of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol